INFI - インフィニティ・ファ―マシュ―ティカルズ (Infinity Pharmaceuticals Inc.) インフィニティ・ファ―マシュ―ティカルズ

 INFIのチャート


 INFIの企業情報

symbol INFI
会社名 Infinity Pharmaceuticals Inc (インフィニティ・ファ―マシュ―ティカルズ)
分野(sector) Health Care   ヘルスケア
産業(industry) Major Pharmaceuticals  
業種 バイオテクノロジ―_メディカルリサ―チ   医療関連(Health Care)
概要 事業概要 インフィニティ・ファーマシューティカルズ(Infinity Pharmaceuticals Inc.)は創薬・新薬開発会社。同社の主力製品は同社が血液悪性腫瘍と炎症性疾患において研究しているクラスI ・PI3K- デルタとPI3K- ガンマの強力な経口阻害剤である。同社のretaspimycin塩酸塩(HCl)は熱ショック蛋白質90(Hsp90)の強力な選択的阻害剤である。ホスホイノシチド3 - キナーゼ(PI3K)は中心ノードとして細胞表面受容体から下流の生化学的事象へ信号を伝達する重要な細胞信号伝達蛋白質である。同社のこのプログラムにおける主力開発候補は臨床試験が行われた、血液悪性腫瘍と炎症性疾患を形成するクラスI PI3K-デルタ・ガンマの強力な経口阻害剤IPI-145である。血液悪性腫瘍は血液・骨髄の癌であり、慢性リンパ性白血病(CLL)、ホジキンリンパ腫、非ホジキンリンパ腫(NHL)などの白血病とリンパ腫を含む。   インフィニティ・ファ―マシュ―ティカルズは、米国のバイオ医薬品企業。主力製品候補のIPI-145は血液悪性腫瘍と炎症性疾患を対象とする、ホスホイノシチド3-キナ―ゼ(PI3K)のクラスIデルタとガンマアイソフォ―ムの経口阻害剤である。またIPI-443などを参考に、第二のPI3K製品候補、PI3Kデルタとガンマの経口阻害剤を開発。   Infinity Pharmaceuticals, Inc. ('Infinity' or the 'Company'), is a clinical-stage biotechnology company developing eganelisib (IPI-549), a potentially first-in-class, oral, immuno-oncology macrophage reprogramming therapeutic which addresses a fundamental biologic mechanism of immune suppression in cancer in multiple clinical studies. MARIO-275 is a randomized, controlled combination study of eganelisib combined with Opdivo® in I/O naïve urothelial cancer. MARIO-3 is the first eganelisib combination study in front-line advanced cancer patients and is evaluating eganelisib in combination with Tecentriq® and Abraxane® in front-line TNBC and in combination with Tecentriq and Avastin® in front-line RCC. In collaboration with Arcus Biosciences, Infinity is evaluating a checkpoint inhibitor-free, novel combination regimen of eganelisib plus etrumadenant (AB928, a dual adenosine receptor antagonist) plus Doxil® in advanced TNBC patients. In 2019, Infinity completed enrollment in MARIO-1, a Phase 1/1b study evaluating eganelisib as a monotherapy and in combination with Opdivo (nivolumab) in patients with advanced solid tumors including patients refractory to checkpoint inhibitor therapy. With these studies Infinity is evaluating eganelisib in the anti-PD-1 refractory, I/O-naïve, and front-line settings.
本社所在地 784 Memorial Drive Cambridge MA 02139 USA
代表者氏名 Adelene Q. Perkins アデリーンQ.パーキンス
代表者役職名 Chairman of the Board Chief Executive Officer 取締役会長兼最高経営責任者
電話番号 +1 617-453-1000
設立年月日 34759
市場名 NASDAQ National Market System
ipoyear ―年
従業員数 22人
url www.infi.com
nasdaq_url https://www.nasdaq.com/symbol/infi
adr_tso
EBITDA EBITDA(百万ドル) -32.06800
終値(lastsale) 2.45
時価総額(marketcap) 139283842.6
時価総額 時価総額(百万ドル) 144.96890
売上高 売上高(百万ドル) 6.00000
企業価値(EV) 企業価値(EV)(百万ドル) 95.80390
当期純利益 当期純利益(百万ドル) 43.64100
決算概要 決算概要 BRIEF: For the six months ended 30 June 2018 Infinity Pharmaceuticals Inc. revenues was not reported. Net loss decreased 40% to $16.4M. Lower net loss reflects Other expense decrease from $6.9M (expense) to $0K Other General and administrative decrease of 44% to $5.5M (expense) Stock Based compensation in General and decrease of 46% to $1.5M (expense). Basic Earnings per Share excluding Extraordinary Items increased from -$0.54 to -$0.31.

 INFIのテクニカル分析


 INFIのニュース

   How Infinity Pharmaceuticals Inc. (NASDAQ: INFI) Could Be A Loss Maker Since It Is Down -46.67% YTD?  2022/04/02 12:00:00 Marketing Sentinel
During the last session, Infinity Pharmaceuticals Inc. (NASDAQ:INFI)’s traded shares were 0.76 million, with the beta value of the company hitting 2.07. At the end of the trading day, the stock’s price was $1.20, reflecting an intraday gain of 5.26% or $0.06. The 52-week high for the INFI share is $3.89, that puts it down … How Infinity Pharmaceuticals Inc. (NASDAQ: INFI) Could Be A Loss Maker Since It Is Down -46.67% YTD? Read More »
   Infinity Pharmaceuticals stock soars 25% after FY21 revenue beat  2022/03/30 16:38:06 Seeking Alpha
Shares of biotechnology company Infinity Pharmaceuticals <> soar as much as 28% a day after reporting better-than-expected FY revenue, helped by higher royalties.Company posts…
   Infinity Pharmaceuticals, Inc. (INFI) CEO Adelene Perkins on Q4 2021 Results - Earnings Call Transcript  2022/03/30 01:30:19 Seeking Alpha
   Infinity Pharmaceuticals GAAP EPS of -$0.53 in-line, revenue of $1.86M beats by $0.16M  2022/03/29 20:12:07 Seeking Alpha
Infinity Pharmaceuticals press release (INFI): FY GAAP EPS of -$0.53 in-line.Revenue of $1.86M (+8.8% Y/Y) beats by $0.16M.Total cash, cash equivalents and available-for-sale…
   Infinity Pharmaceuticals Reports Full Year 2021 Financial Results and Provides Company Highlights  2022/03/29 20:05:00 Business Wire
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Infinity Pharmaceuticals, Inc. (NASDAQ: INFI) (“Infinity” or the “Company”), a clinical-stage biotechnology company developing eganelisib, a first-in-class, oral, immuno-oncology macrophage reprogramming therapeutic, today announced its full year 2021 financial results and provided corporate highlights. “Based on the strength and breadth of eganelisib’s activity across mTNBC and mUC as well as ovarian cancer, SCCHN, and melanoma, we raised $92 million in early
   Infinity Pharmaceuticals, Inc. (NASDAQ:INFI) Expected to Announce Quarterly Sales of $410,000.00  2021/11/08 04:46:44 Transcript Daily
Wall Street analysts expect that Infinity Pharmaceuticals, Inc. (NASDAQ:INFI) will post sales of $410,000.00 for the current quarter, Zacks Investment Research reports. Five analysts have made estimates for Infinity Pharmaceuticals earnings, with estimates ranging from $200,000.00 to $550,000.00. Infinity Pharmaceuticals posted sales of $440,000.00 in the same quarter last year, which suggests a negative year-over-year []
   $410,000.00 in Sales Expected for Infinity Pharmaceuticals, Inc. (NASDAQ:INFI) This Quarter  2021/11/08 03:32:41 Dakota Financial News
Brokerages expect Infinity Pharmaceuticals, Inc. (NASDAQ:INFI) to report sales of $410,000.00 for the current quarter, according to Zacks Investment Research. Five analysts have provided estimates for Infinity Pharmaceuticals earnings, with the highest sales estimate coming in at $550,000.00 and the lowest estimate coming in at $200,000.00. Infinity Pharmaceuticals reported sales of $440,000.00 in the same []
   Infinity Pharmaceuticals, Inc. to Post FY2021 Earnings of ($0.54) Per Share, Piper Sandler Forecasts (NASDAQ:INFI)  2021/11/06 05:52:41 Transcript Daily
Infinity Pharmaceuticals, Inc. (NASDAQ:INFI) Equities research analysts at Piper Sandler raised their FY2021 earnings estimates for shares of Infinity Pharmaceuticals in a research note issued on Tuesday, November 2nd. Piper Sandler analyst E. Tenthoff now forecasts that the biotechnology company will post earnings of ($0.54) per share for the year, up from their previous []
   Infinity Pharmaceuticals Inc. (NASDAQ: INFI) Stock: Does It Have More Upside?  2021/11/03 17:00:00 Marketing Sentinel
In todays recent session, 0.74 million shares of the Infinity Pharmaceuticals Inc. (NASDAQ:INFI) have been traded, and its beta is 1.93. Most recently the companys share price was $2.75, and it changed around $0.12 or 4.65% from the last close, which brings the market valuation of the company to $237.02M. INFI at last check was Infinity Pharmaceuticals Inc. (NASDAQ: INFI) Stock: Does It Have More Upside? Read More »
   Brokerages Set Infinity Pharmaceuticals, Inc. (NASDAQ:INFI) Price Target at $8.95  2021/11/03 03:02:41 Dakota Financial News
Infinity Pharmaceuticals, Inc. (NASDAQ:INFI) has been assigned a consensus recommendation of Buy from the ten research firms that are presently covering the stock, MarketBeat Ratings reports. Ten research analysts have rated the stock with a buy rating. The average 1-year price target among analysts that have updated their coverage on the stock in the last []
   Pleasing stocks: Adverum Biotechnologies, Inc. (NASDAQ:ADVM 1.46%), Infinity Pharmaceuticals, Inc. (NASDAQ:INFI 3.26%)  2021/10/08 00:42:20 Stock Equity
There are two main reasons why moving averages are useful in forex trading: moving averages help traders define trend recognize changes in trend. Now well have a look on, SMA50 The post Pleasing stocks: Adverum Biotechnologies, Inc. (NASDAQ:ADVM 1.46%), Infinity Pharmaceuticals, Inc. (NASDAQ:INFI 3.26%) appeared first on Stocks Equity .
   Mesmerizing stocks: PG&E Corporation (NYSE:PCG 0.68%), Infinity Pharmaceuticals, Inc. (NASDAQ:INFI -3.51%)  2021/10/02 00:22:13 Stock Equity
There are two main reasons why moving averages are useful in forex trading: moving averages help traders define trend recognize changes in trend. Now well have a look on, SMA50 The post Mesmerizing stocks: PG&E Corporation (NYSE:PCG 0.68%), Infinity Pharmaceuticals, Inc. (NASDAQ:INFI -3.51%) appeared first on Stocks Equity .
   Seducing stocks: Infinity Pharmaceuticals, Inc. (NASDAQ:INFI -4.31%), Alfi, Inc. (NASDAQ:ALF -2.42%)  2021/09/26 23:20:24 Stock Equity
There are two main reasons why moving averages are useful in forex trading: moving averages help traders define trend recognize changes in trend. Now well have a look on, SMA50 The post Seducing stocks: Infinity Pharmaceuticals, Inc. (NASDAQ:INFI -4.31%), Alfi, Inc. (NASDAQ:ALF -2.42%) appeared first on Stocks Equity .
   Holding stocks: Facebook, Inc. (NASDAQ:FB 1.94%), Infinity Pharmaceuticals, Inc. (NASDAQ:INFI -3.37%)  2021/09/25 01:23:14 Stock Equity
There are two main reasons why moving averages are useful in forex trading: moving averages help traders define trend recognize changes in trend. Now well have a look on, SMA50 The post Holding stocks: Facebook, Inc. (NASDAQ:FB 1.94%), Infinity Pharmaceuticals, Inc. (NASDAQ:INFI -3.37%) appeared first on Stocks Equity .
   Honest Ways To pick this stocks: Citius Pharmaceuticals, Inc. (NASDAQ:CTXR 0.81%), Infinity Pharmaceuticals, Inc. (NASDAQ:INFI 3.40%)  2021/09/21 23:32:09 Stock Equity
There are two main reasons why moving averages are useful in forex trading: moving averages help traders define trend recognize changes in trend. Now well have a look on, SMA50 The post Honest Ways To pick this stocks: Citius Pharmaceuticals, Inc. (NASDAQ:CTXR 0.81%), Infinity Pharmaceuticals, Inc. (NASDAQ:INFI 3.40%) appeared first on Stocks Equity .

 関連キーワード  (バイオテクノロジ―_メディカルリサ―チ 米国株 インフィニティ・ファ―マシュ―ティカルズ INFI Infinity Pharmaceuticals Inc.)

 twitter  (公式ツイッターやCEOツイッターなど)